1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | Icosapent ethyl (eicosapentaenoic acid ethyl ester, EPA-EE) |
| brand | String | Vascepa |
| structure | File | |
| classes | List of String, delimiter: , | [[:Category:Lipid-lowering_agents|Lipid-lowering agent]] • [[:Category:Omega-3_fatty_acids|Omega-3 fatty acid]] |
| mechanism | String | |
| uses | String | '"`UNIQ--vote-000013CF-QINU`"', '"`UNIQ--vote-000013D0-QINU`"' |
| starting_dose | String | 2 g PO BID with meals (4 g/d total) |
| preparations | String | 0.5 g, 1 g capsules |
| fda_max | String | 4 g/d |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral |
| onset | String | Triglyceride lowering at 4-8 weeks; CV benefit emerges over months |
| duration | String | 12 hours |
| halflife | String | ~89 hours (EPA, the active metabolite)'"`UNIQ--ref-000013D1-QINU`"' |
| bioavailability | String | Substantially improved with high-fat meal; take with food'"`UNIQ--ref-000013D2-QINU`"' |
| pregnancy | String | Limited data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> |
| legal | String | [[USLegal:Prescription only|Rx-only]] in US |
